Conditioning with high-dose cyclophosphamide may not be sufficient to provide a long-termn remission of paroxysmal nocturnal hemoglobinuria following syngeneic peripheral blood stem cell transplantation

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A patient with paroxysmal nocturnal hemoglobinuria (PNH) received a syngeneic peripheral blood stem cell transplant (PBSCT) with high-dose cyclophosphamide (CY) conditioning. He had a reasonable engraftment and complete hematologic recovery. However, at 12 months after PBSCT, he became symptomatic and peripheral blood cells were almost entirely composed of glycosylphosphatidylinositol-anchored proteins deficient cells. This case suggests that high-dose CY may not exert a significant effect on PNH clones in the long term, although it had been effective in allogeneic BMT. In view of the possible autoimmune basis, it seems to be necessary to include other immunosuppressive therapy including ALG in addition to CY.

Original languageEnglish
Pages (from-to)987-988
Number of pages2
JournalBone Marrow Transplantation
Volume28
Issue number10
DOIs
StatePublished - 2001

Keywords

  • High-dose cyclophosphamide
  • Paroxysmal nocturnal hemoglobinuria
  • Syngeneic peripheral blood stem cell transplantation

Fingerprint

Dive into the research topics of 'Conditioning with high-dose cyclophosphamide may not be sufficient to provide a long-termn remission of paroxysmal nocturnal hemoglobinuria following syngeneic peripheral blood stem cell transplantation'. Together they form a unique fingerprint.

Cite this